Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bosutinib in amyotrophic lateral sclerosis
jRCT2051220002Phase 2Active, not recruiting
- Sponsor
- Japan Agency for Medical Research and Development
- Start
- May 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of bosutinib in amyotrophic lateral sclerosis (ALS), sponsored by Japan Agency for Medical Research and Development. Started May 2022; status: active, not recruiting.
02
Drugs
bosutinib
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on jRCT2051220002.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051220002.